

Adverse Effects, Health Service Engagement, and Service Satisfaction Among Anabolic Androgenic Steroid Users

Contemporary Drug Problems
2017, Vol. 44(1) 69-83
© The Author(s) 2017
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/0091450917694268
journals.sagepub.com/home/cdx


Renee Zahnow¹, Jim McVeigh², Jason Ferris¹, and Adam Winstock^{3,4}

Abstract

There are a number of adverse health effects associated with the use of anabolic androgenic steroids (AAS), ranging from mood disturbances to gynecomastia and impaired sexual function. Despite the potentially serious nature of adverse effects, evidence suggests that users are reluctant to seek medical assistance. This study explores factors associated with health service engagement and treatments related to service satisfaction among a sample of AAS users. The analyses are based on a sample of 195 respondents from the Global Drug Survey 2015 who reported using steroids in the previous 12-month period *and* experiencing concerns about adverse health effects. The results indicate reluctance among AAS users to engage with health services, with only 35.23% reporting that they visited a doctor when experiencing concerns about adverse effects. Concern about sexual function increased the likelihood that users engaged with health services, while concern about changes in sexual organs decreased the odds of service engagement. Among AAS users who engaged with health services, individuals who received a mental health assessment or diabetes test rated the service as more helpful than those who did not; a finding that resonates with literature indicating a desire among AAS users to monitor the health impacts of their drug use and respond to issues as they arise. While more research is needed, the present results underscore a need for nonjudgmental health services aimed at assisting AAS users to monitor adverse effects and minimize harm through early intervention.

Keywords

steroids, PIEDs, help-seeking, Global Drug Survey, health services

¹ Institute for Social Science Research, The University of Queensland, St. Lucia, Queensland, Australia

² Centre for Public Health, Liverpool John Moores University, Liverpool, UK

³ Global Drug Survey, London, UK

⁴ Kings College London, London, UK

Received October 19, 2016. Accepted for publication January 26, 2017.

Corresponding Author:

Renee Zahnow, Institute for Social Science Research, The University of Queensland, St. Lucia, Queensland 4072, Australia.
Email: r.zahnow@uq.edu.au

Introduction

The use of anabolic androgenic steroids (AAS) and associated performance and image enhancing drugs (PIEDs) is not new. In the past decade, efforts have been made to eliminate the use of PIEDs by professional sportspersons and elite athletes. Yet, there is some evidence of a concomitant increase during this time in AAS and PIEDs use in the general population (Iversen, Topp, Wand, & Maher, 2013; McCabe, Brower, West, Nelson, & Wechsler, 2007; McVeigh & Begley, 2016; McVeigh, Beynon, & Bellis, 2003). Estimated lifetime prevalence rates, based on population surveys in Australia (Dunn, 2010), Norway (Sagoe et al., 2015), and the USA (Pope et al., 2014), range from less than 1–6% depending on sample characteristics. A recent meta-analysis of 187 studies reports a global lifetime prevalence rate of 3.3% (Sagoe, Molde, Andreassen, Torsheim, & Pallesen, 2014).

While the prevalence of AAS use in the general population appears to be relatively low, the perception that use is increasing, particularly among young, recreational gym goers and nonathletes, is ubiquitous (Bojsen-Møller & Christiansen, 2010; Chandler & McVeigh, 2013; Evans-Brown, Kimergård & McVeigh, 2009; Kanayama & Pope, 2012b; Kimergård & McVeigh, 2014a; Sagoe et al., 2014). Recreationally, AAS are used to increase muscle mass, improve physical appearance, and enhance strength or athletic performance (Brennan, Wells, & Van Hout, 2016; Ip, Barnett, Tenerowicz, & Perry, 2011; Ip et al., 2015). Reasons for initiating use include body dissatisfaction (Kimergård, 2015), low confidence or poor self-esteem (Cohen, Collins, Darkes, & Gwartney, 2007; Maycock & Howat, 2009), safety and security (Maycock & Howat, 2009), to improve social status (Griffiths, Henshaw, McKay, & Dunn, 2015; Maycock & Howat, 2009; Seer, Fraser, Moore, & Murphy, 2015), or to fit into a “fitness” lifestyle or identity (Ravn & Coffey, 2016).

While health and fitness pursuits are often cited as the main reasons for using AAS (Brennan et al., 2016; Ip et al., 2011; Ip et al., 2015), research has shown that the use of AAS is associated with a number of adverse health effects (Kanayama & Pope, 2012a). Some of these effects are acute in nature and naturally subside with cessation of AAS use, while others are chronic health conditions that develop from long-term AAS use (Pope & Kanayama, 2015; Pope et al., 2013). Physical side effects include cardiovascular damage, liver disorders (especially if administered orally), testicular atrophy, gynecomastia, and loss of sexual function (Pope et al., 2013). An association between AAS use and poorer mental health outcomes has also been reported (Lindqvist et al., 2013). Acute effects of AAS use are also well described in the literature particularly in relation to “stacking” (Sagoe et al., 2015), unsafe injecting practices (Dunn, McKay, & Iversen, 2014; Iversen, Hope, & McVeigh, 2016), and/or the use of illicitly manufactured products (Evans-Brown et al., 2009). Research has also demonstrated a link between AAS use and negative psychological states including anger, depression, and anxiety (Pope et al., 2005).

Despite the potentially serious nature of adverse effects, evidence suggests that AAS users are reluctant to seek medical assistance or to reveal their AAS use to their doctor (Pope, Kanayama, Ionescu-Pioggia, & Hudson, 2004). A recent purposive survey of 94 steroid and image enhancing drug users in the UK found that only 6% reported seeking medical assistance when they experienced adverse effects related to AAS use. Users cited lack of understanding from their doctor as one of the reasons they did not engage with health services (Chandler & McVeigh, 2013). Similarly, a recent convenience study of injecting AAS users revealed only a minority (17%) of AAS injectors who experienced redness, swelling, or tenderness around the injection site had ever sought treatment (Hope et al., 2015). While these studies, based on samples of bodybuilders (Chandler & McVeigh, 2013) and needle exchange attendees (Hope et al., 2015), provide some insight into the health service experiences of AAS users, this type of detailed information on health service engagement and satisfaction is not currently available from general population drug surveys.

In order to develop appropriate health service responses to AAS use, additional information on health service engagement, treatment, and satisfaction is required from AAS users in the general population. The Global Drug Survey (GDS) is an online, anonymous survey designed to capture in-depth information about the use of alcohol, tobacco, and illicit substances. The GDS includes a range of questions about the use of AAS including items relating to adverse effects, health service engagement, and service satisfaction. Using a sample of respondents from the GDS 2015 who reported using steroids in the previous 12-month period, the current study identifies factors associated with health service engagement and examines treatments associated with health service satisfaction. Given the growing number and diversity of AAS users (Pope & Kanayama, 2015; Rowe, Berger, & Copeland, 2016; Seer et al., 2015), minimizing harm associated with AAS use is an important public health concern. The aim of the current research is to better understand the reasons for health service engagement among AAS users. This knowledge is vital to inform the development of health services that are aligned with the needs of AAS users, encourage health service engagement among this group, and, in turn, minimize drug-related harms.

Method

Design

The GDS is an annual, international, online survey of drug use which is self-completed, largely by younger individuals, on a self-nominating, anonymous basis. The most recent survey (GDS, 2015) collected data between November 2014 and January 2015. A total of 89,509 responses were completed during this time. The survey was promoted in partnership with a range of media including national newspapers, magazines, websites, and social media outlets (GDS, 2015) and was available in 11 languages (English, German, Greek, Polish, French, Italian, Spanish, Portuguese, Flemish, Hungarian, and Danish). The GDS sample is opportunistic and not intended to be representative of any particular population group. Other publications provide details on the design, utility, and limitations of the GDS (Barratt, Ferris, & Winstock, 2014; GDS, 2015; Winstock, Lynskey, Borschmann, & Waldron, 2015).

GDS respondents were asked whether they had used injectable anabolic steroids or oral anabolic steroids in their lifetime and in the last 12 months. The total number of GDS participants who reported lifetime steroid use was 1,000. This was 1.1% of the total survey sample. In the current study, the analytic sample is restricted to those who (1) indicated that they used AAS during the 12 months prior to the survey and (2) experienced concerns about adverse effects related to AAS use ($n = 195$).

Analyses and Measures

The analyses proceed in three stages. All measures are drawn from the GDS 2015. Stage 1 is a logistic regression analysis examining factors associated with health service engagement. The dependent variable is a dichotomous indicator drawn from an item in the GDS that asked respondents who reported using AAS in the last 12 months whether or not they had discussed health concerns related to their AAS use with their family doctor (yes/no). The key independent variables are five dichotomous indicators capturing concerns about mood/mental health, image, sexual function, sexual organs, and organ health. The five variables were constructed from 17 items on the GDS that asked individuals who reported using AAS in the last 12 months to report on a scale of 1 (*not at all worried*) to 3 (*worried a lot*) how worried they were about 7 mental health and 10 physical health issues associated with AAS use. For each of the five variables, respondents were given a score of 1 if they reported concern about the health issue and a score of 0 if they reported no concerns about the health issue. The construction of the five measures was based on existing literature that discusses the adverse effects of AAS use as




Figure 1. Multiple components analysis (MCA) of items measuring worry about adverse effects of anabolic androgenic steroid use.

comprising both physical and mental health components (Kanayama & Pope, 2012a; Lindqvist et al., 2013; Onakomaiya & Henderson, 2016; Quaglio et al., 2009). Physical health concerns were further delineated into those associated with sexual organs; sexual function and organ health as responses may be expected to vary by sex and method of administration, respectively. Item groupings were confirmed using multiple components analysis (see Figure 1) and are reported in Table 1. Control variables including age, sex (1 = *female*, 2 = *male*), region of residence (1 = *Europe*, 2 = *North America*, 3 = *South America*, 4 = *Australia/New Zealand*, and 5 = *Asia/Africa and Middle East*), ethnicity (0 = *Caucasian*, 1 = *other*), poly-PIEDs use (0 = *no AAS only*, 1 = *yes AAS plus at least one other PIED*), and method of AAS administration (0 = *oral*, 1 = *inject only*, and 2 = *both oral and inject*) were also included in the logistic regression models.

Stage 2 of the analyses establishes the proportion of recent AAS users who engaged with health services about their AAS use and examines the bivariate relationships between treatments received and satisfaction with health services, measured using 2 items from the GDS. Individuals who reported using AAS in the last 12 months and indicated they had engaged with health services in relation to their AAS use ($n = 68$) were asked to rate their experience of raising their steroid use with their doctor on a scale of 1 (*very poor*) to 5 (*very good*). They were also asked to report on a scale of 1 (*not helpful*) to 4 (*very helpful*) how helpful their doctor was in addressing health concerns related to their AAS use. Aspects of treatment were assessed using 8 individual items. Respondents were asked to indicate whether the following investigations/conversations were carried out by their doctor (yes/no): physical examination, blood pressure, assessment of my mood, blood tests to assess my liver function, diabetes test, electrocardiograph (ECG), screening for hepatitis B/C and HIV, and discussion about safer injecting. The Wilcoxon–Mann–Whitney test¹ was used to assess statistically significant associations between treatments received and each of the variables capturing satisfaction with health services. A two-sided p value of $<.05$ was considered statistically significant.

Stage 3 of the analyses describes frequently reported reasons for *not* engaging with health services despite experiencing concerns about AAS-related health issues. Those respondents who indicated that

Table 1. Summary Statistics.

Characteristics	<i>n</i>	%
Age mean = 29.8 (min = 17, max = 72)		
Sex		
Male	253	(79.56)
Female	59	(18.55)
Region of residence		
Europe	166	(52.20)
North America	34	(10.69)
South Americas	61	(19.18)
Oceania	51	(16.04)
Asia, Africa/Middle East	6	(1.89)
Ethnicity		
White	263	(82.70)
Non-White	55	(17.30)
Poly-PIED use last 12 months		
No AAS only	174	(54.72)
Yes AAS plus at least one other	144	(45.28)
Method of use		
Oral only	63	(28.13)
Inject only	81	(36.16)
Both oral and inject	80	(35.71)
Worry about adverse effects		
Mood/mental health		
Anger/aggression		
Not at all worried	122	(61.31)
Worried a little or a lot	77	(38.69)
Depression/low mood		
Not at all worried	125	(63.45)
Worried a little or a lot	72	(36.55)
Rapid fluctuation in mood		
Not at all worried	118	(60.51)
Worried a little or a lot	77	(39.49)
Irrational excitability/elevation in mood		
Not at all worried	129	(65.48)
Worried a little or a lot	68	(34.52)
Restlessness/irritability		
Not at all worried	114	(57.58)
Worried a little or a lot	84	(42.42)
Loss of interest in other things		
Not at all worried	141	(72.31)
Worried a little or a lot	54	(27.69)
Quality of relationship with others		
Not at all worried	130	(66.67)
Worried a little or a lot	65	(33.33)
Image		
Hair loss		
Not at all worried	119	(61.98)
Worried a little or a lot	73	(38.02)
Hair gain		
Not at all worried	135	(71.43)
Worried a little or a lot	54	(28.57)

(continued)

Table 1. (continued)

Characteristics	<i>n</i>	%
Skin conditions		
Not at all worried	84	(43.75)
Worried a little or a lot	106	(56.25)
Sexual function		
Sexual function		
Not at all worried	106	(53.81)
Worried a little or a lot	91	(46.19)
Sexual organs		
Effect on sexual organs		
Not at all worried	98	(50.78)
Worried a little or a lot	95	(49.22)
Reduction in breast size		
Not at all worried	164	(91.11)
Worried a little or a lot	16	(8.89)
Growth of breasts ^a		
Not at all worried	103	(54.50)
Worried a little or a lot	86	(45.50)
Increase in breast size		
Not at all worried	148	(82.68)
Worried a little or a lot	31	(17.32)
Organ health		
Heart		
Not at all worried	87	(45.08)
Worried a little or a lot	106	(54.92)
Liver function		
Not at all worried	86	(44.79)
Worried a little or a lot	106	(55.21)

Note. PIED = performance and image enhancing drug; AAS = anabolic androgenic steroid.

^aWe note this item is only applicable to male participants.

they did not visit their family doctor about health concerns related to their AAS use were asked whether this was for any of the following reasons (yes/no): shame/stigma, did not think the doctor would be able/knowledgeable enough to help, did not think the doctor would be willing to help, the concerns were not significant enough, and worries over the impact on health insurance. All analyses were conducted using STATA 13.0. The results of each stage of the analyses are reported below.

Results

The total number of GDS respondents who reported using AAS in the 12-month period preceding the survey was 318. This sample of recent AAS users comprised 253 (79.56%) men and 59 (18.55%) women with a mean age of 29.8 years ($SD = 12.35$).² Of those who reported using AAS during the last 12 months, 117 (36%) did not record any responses to questions asking about adverse effects. The 117 respondents who did not report any concerns about adverse effects were eliminated from the analyses leaving an analytic sample of 195. Chi-square analyses and independent samples *t* tests were conducted to compare the demographic characteristics of the 117 participants who did not record any responses to questions about adverse effects to the analytic sample. There were no significant differences between the two groups of respondents in relation to age, employment status, ethnicity, or highest level of education. Females were more likely to be nonresponders than males, $\chi^2(1, N =$

201) = 49.92, $p < .001$. Prior research associates women's reluctance to divulge steroid use with their engagement in drug-tested bodybuilding competitions and stigma (Korika, Lenehan, & McVeigh, 1996). Descriptive statistics are displayed in Table 1.

Stage 1: Factors Associated With Health Service Engagement

Sixty-eight (35.23%) respondents reported visiting a doctor within the last year in relation to their AAS use. This subsample comprised 9 (13.24%) women and 59 (86.76%) men with an average age of 35.94 years ($SD = 13.33$). Bivariate statistics revealed that women who experienced concerns about adverse effects were more likely to engage with health services than men, $\chi^2(1, N = 195) = 5.13, p < .05$. On average, AAS users who engaged with health services were significantly older than those who did not ($t = -5.03, p < .001$).

Logistic regression models revealed that AAS users who were concerned about the effects of their drug use on sexual function were more likely to visit a doctor in relation to their AAS use than those who did not experience worry about sexual function ($OR = 4.02, p < .01$). Alternately, individuals who experienced concern about the impact of their AAS use on sexual organs were less likely to visit a doctor than individuals who did not experience this concern ($OR = 0.30, p < .05$). Males were less likely to report visiting a doctor about their AAS use than females ($OR = 0.09, p < .01$). Because it is well known that oral steroid use is associated with liver problems but injecting use is not, an interaction between method of administration and concern about organ health was included in the model. The interaction was moderately significant and indicated that for injecting AAS users, worry about organ health was associated with greater likelihood of visiting a doctor while the opposite was true for noninjectors.³ Logistic regression results are reported in Table 2.

Stage 2: Health Service Satisfaction Among AAS Users Who Visited a Doctor

Ratings of health service helpfulness and overall experience did not differ by sex ($p = 1.00; p = .75$, fisher's exact test) and were not significantly associated with age ($b = 0.03, p = .18; b = 0.25, p = .15$).⁴ Of the 68 AAS users who visited a doctor within the last year, 54 (79.41%) reported receiving a physical examination and 55 (80.88%) reported receiving blood tests to assess liver function. These were the most frequently reported treatments received. Alternately, only 23 (33.82%) respondents reported having a discussion with the doctor about their mood and 26 (38.42%) reported receiving an ECG to assess cardiac health (Table 3).

Individuals who reported discussing their mood with the doctor ($z = -2.71, p < .01$) and those who were tested for diabetes ($z = -2.10, p < .05$) were more likely than those who did not receive these treatments to rate the health service as helpful or very helpful. Individuals who were screened for hepatitis B/C and HIV were more likely than those who did not receive this treatment to rate their overall experience with the doctor as good or very good ($z = -2.62, p < .01$). Other treatments, including physical examination, blood pressure check, ECG, safe injecting education, and blood tests for liver function, were not significantly associated with health service satisfaction.

Stage 3: Reasons for Not Engaging With Health Services

One hundred and thirty (67.36%) respondents did not visit a doctor despite being worried about adverse effects related to their AAS use. The most frequently cited reason for not engaging with health services was that the condition was not significant enough ($n = 70, 53.85%$). Approximately one quarter of respondents reported that they did not engage with health services because they were not confident that their doctor had the knowledge to help ($n = 31, 23.85%$) or they were concerned about the stigma/shame associated with AAS use ($n = 29, 22.31%$). Eighteen respondents did not think their

Table 2. Logistic Regression Predicting Doctors Visit.

	Full Model		Interaction Model	
	OR	95% CI	OR	95% CI
User characteristics				
Age	1.03	[0.82, 1.31]	1.03	[0.81, 1.32]
Age × Age	1.00	[0.99, 1.00]	1.00	[0.99, 1.00]
Male	0.10**	[0.02, 0.40]	0.10**	[0.02, 0.47]
Region of residence (ref: Europe)				
North America	6.26**	[1.36, 28.8]	5.11**	[1.08, 24.2]
South Americas	1.58	[0.63, 3.95]	1.51	[0.60, 3.82]
Oceania	1.49	[0.50, 4.41]	1.42	[0.45, 4.46]
Asia, Africa/Middle East	0.34	[0.03, 4.12]	0.31	[0.02, 4.01]
Poly-PIEDs use in last 12 months (ref: AAS only)	0.76	[0.34, 1.68]	0.80	[0.35, 1.83]
Method of administration (ref: oral only)				
Inject only	3.39	[1.09, 10.6]	1.41	[0.18, 10.9]
Both oral and inject	3.14	[1.01, 9.75]	5.36	[0.78, 36.7]
Worry of adverse effects				
Mood/mental health	0.65	[0.34, 1.68]	0.60	[0.25, 1.44]
Image	1.29	[0.50, 3.31]	1.14	[0.41, 1.61]
Sexual function	4.02**	[1.56, 10.3]	4.09**	[1.56, 10.7]
Sexual organs	0.30*	[0.11, 0.86]	0.32*	[0.11, 0.91]
Organ health	1.05	[0.43, 2.60]	0.41	[0.11, 1.51]
Interaction: Method of Admin. × Organ Health				
Oral Only × Organ Health			2.42	[0.26, 22.6]
Inject Only × Organ Health			7.93*	[1.23, 51.3]
Model information				
Constant	3.25	[0.03, 351]	3.05	[0.03, 348]
Wald χ^2		58.34		63.32
LR test of improvement		-89.22		-86.73

Note. $n = 186$. PIED = performance and image enhancing drug; AAS = anabolic androgenic steroid; LR = likelihood-ratio test. Significant: * $p < .05$. ** $p < .01$. *** $p < .001$.

doctor would be willing to help them with an issue related to their AAS use (13.85%). Only three respondents cited concern about health insurance as a factor in their decision not to engage with health services in relation to their AAS use (2.31%; Table 4).

Discussion

In the current study, we explored health concerns associated with visiting a doctor among a sample of recent AAS users and, among those who did not visit a doctor despite their health concerns, we looked at reasons given for not engaging with health services. Our findings show that only a minority of AAS users engage with health services when they experience health-related concerns about their AAS use, but receiving care specific to conditions associated with AAS use, as opposed to more generic treatments, facilitated greater health service satisfaction. Overall, our findings suggest that to encourage help seeking among AAS users, health service providers must demonstrate that they are both non-judgmental and knowledgeable about the use of AAS. These findings offer important insights in the context of AAS use being associated with a range of both chronic and acute physical and mental health issues (Kanayama & Pope, 2012a; Lindqvist et al., 2013; McVeigh & Begley, 2016). The incidence and severity of these AAS-related harms may be ameliorated if users engage with health services when concerns first arise. Yet, research suggests that AAS users are reluctant to engage with health services

Table 3. Treatment Received and Service Satisfaction.

	N = 68	%	Helpfulness (z)	Overall experience (z)
Physical examination				
Yes	54	79.41	1.42	1.00
No	14	20.59		
Blood pressure				
Yes	50	26.47	-0.47	0.48
No	18	73.53		
Assessment of mood				
Yes	23	33.82	2.71**	1.50
No	45	66.18		
Blood tests to assess liver function				
Yes	55	80.88	0.05	0.19
No	13	19.12		
Diabetes test				
Yes	28	41.18	2.10*	1.09
No	40	58.82		
ECG				
Yes	26	38.24	1.37	0.98
No	42	61.76		
Screening for hepatitis B/C and HIV				
Yes	28	41.18	1.68	2.62**
No	40	58.82		
Discussion about safer injecting				
Yes	27	39.71	0.97	0.90
No	41	60.29		

Table 4. Reasons for Not Visiting a Doctor.

	N = 130	%
Shame/stigma		
Yes	29	22.31
No	101	77.69
Did not think the doctor would be able to/knowledgeable enough to help		
Yes	31	23.85
No	99	76.15
Did not think the doctor would be willing to help		
Yes	18	13.85
No	112	86.15
Concerns were not significant enough		
Yes	70	53.85
No	60	46.15
Worry over the impact on health insurance		
Yes	3	2.31
No	127	97.69

and little is known about the types of treatments that would encourage help seeking among this group (Dunn, Henshaw, & McKay, 2016; Kimergård & McVeigh, 2014b; Pope & Kanayama, 2015). Our study begins to address this knowledge gap.

The results reveal three key findings. First, in line with previous research, we find that a minority of AAS users (36.23%) engage with health services when they experience concerns related to their AAS

use. Commonly reported reasons for not engaging with health services reflected those documented in previous studies: the problem was not significant enough; lack of confidence in doctors' knowledge of AAS; and concerns about stigma associated with AAS use (Chandler & McVeigh, 2013; Hope et al., 2015; Pope et al., 2004; Yu, Hildebrandt, & Lanzieri, 2015).

Second, we found that two treatments, mood assessments and diabetes tests, were associated with higher ratings of service helpfulness, and one treatment, screening for hepatitis B/C and HIV, was associated with higher ratings of overall experience with the doctor. Treatments that aimed to assess health issues related to specific AAS side effects (i.e., diabetes test for insulin resistance, hepatitis B/C and HIV screening, and mood assessment), as opposed to more generic treatments (i.e., physical examination, general blood test), were associated with greater service satisfaction. When AAS users receive treatments that can be associated with specific, well-documented side effects of AAS use, such as insulin resistance, depression (particularly during off-cycle), or blood-borne diseases, this may indicate to the user that the doctor is knowledgeable, nonjudgmental, and willing to monitor and manage their AAS-related health issues. Alternately, when AAS users receive more generic treatments, such as a physical examination or general blood test, they may perceive that the doctor has limited knowledge of health issues specific to AAS use and find the health service less helpful for their needs.

Additionally, screening for specific health conditions may be perceived as helpful because it allows AAS users to continue using the drugs while monitoring the impact on their health and countering adverse effects with medical interventions. For example, a diabetes test may lead to treatment to counter insulin resistance and prevent hyperglycemia allowing the user to continue taking AAS while managing the adverse effects. Other studies have indicated AAS users' desire to take an active role in monitoring their health (Dunn et al., 2016) and highlight the importance of health service providers to be equipped with knowledge specific to the effects of AAS use (Holland-Hall, 2007; McVeigh & Begley, 2016). In interviews with AAS clinic attendees, Kimergård and McVeigh (2014b) found that AAS users appreciated regular medical testing to identify health issues associated with their AAS use, as it enabled them to take action to counter adverse effects as they arose. This study also reported that steroid clinics were popular among users because service providers were nonjudgmental and knowledgeable about AAS.

The third key finding is that AAS users who were concerned about the impact of their drug use on sexual function were more likely to visit a doctor, while those who were concerned about the effects of AAS on their sexual organs (size increase/decrease) were less likely to engage with health services. A possible explanation for this finding is that AAS users engage with health-care providers when they perceive the condition to be treatable. The second most frequently cited reason for not visiting a doctor to discuss concerns about AAS-related health issues was a perception that a doctor would not be able to help. While it is commonly known that doctors can provide treatment for impotence in the form of prescription medication, users may perceive that doctors cannot do anything to treat changes in sexual organs and this may deter them from engaging with health services. The results also revealed that female users were more likely than males to visit a doctor to discuss health concerns related to their AAS use. This finding was not surprising, given that AAS increase circulating levels of the male reproductive hormone, testosterone, and the potential for adverse health effects to arise from AAS use is greater for women than men (Rasmussen et al., 2016). Greater potential for adverse effects may explain higher levels of engagement with health services among women.

There is limited research on interventions and harm reduction policies for AAS, especially on perceptions of treatment from the users' perspective. Existing studies that examine AAS users' engagement with traditional drug services (i.e., needle and syringe programs (NSPs)) suggest that AAS users are reluctant to attend these services for fear of being labeled as a "drug user" (Brennan et al., 2016; Kimergård & McVeigh, 2014b). Further, NSP workers may be ill-equipped to provide advice on intramuscular injecting and AAS dosing, given that they may be less familiar with steroids

than other illicit substances (Dunn et al., 2014; Seer et al., 2015). Given the reluctance of AAS users to engage with traditional drug services (Brennan et al., 2016; Kimergård & McVeigh, 2014b), family doctors and general practitioners may be an important avenue for help seeking among this group. Our findings suggest that doctors can better address the needs of AAS users by assisting them to monitor the impact of their drug use on their physical and mental health through regular screening for known side effects of AAS and countering health issues as they arise.

Our findings support the views of previous scholars who have called for better training and education for doctors, so they can provide credible information to AAS users (Chandler & McVeigh, 2013; Pope et al., 2004). Two of the main reasons for *not* engaging with health services were lack of confidence in doctors' knowledge of AAS and stigma. To be perceived as a credible source of health advice, health service providers must acknowledge the benefits of AAS (Holland-Hall, 2007). While acknowledging the benefits of AAS use, providers should also offer advice on alternative avenues to achieving body and strength goals. Referral to a nutritionist, strength coach or mental health service may be appropriate (Holland-Hall, 2007). Education and training facilitated by current and/or previous AAS users may help to challenge stereotypes of AAS users among health-care providers and create an opportunity for service providers to learn about the experience of AAS use firsthand. Education should also focus on helping health service providers to find subtle ways to demonstrate a nonjudgmental attitude and encourage open conversation about drug use with their patients. This may be achieved by engaging in open discussions about health, mood, and well-being with patients presenting for non-drug-related health issues who may be at high risk of AAS use, for example, individuals presenting with sports/activity-related injuries, individuals from high-risk industries (e.g., police, security) presenting for work-related physicals, and young men reporting sexual dysfunction and/or body dissatisfaction. These types of discussions may also help to identify reasons for AAS use such as body dissatisfaction, insecurities, bullying, and/or pressure to perform (Hanley Santos & Coomber, 2016; Holland-Hall, 2007; Ip et al., 2015; Kanayama & Pope, 2012a; Kimergård, 2015; Maycock & Howat, 2009).

Limitations

This study has a number of strengths and limitations worth noting. The GDS is an established survey that collects data on drug use from an international sample of general population users. Information about health service engagement collected from general population AAS users is rare and access to the GDS data brings a unique aspect to this study. Most other surveys that have sought to explore behaviors, including the uptake of health services, have directly targeted steroid users in the gym environment (Davies, Smith, & Collier, 2011; Lindqvist et al., 2013; Pope et al., 2004) through needle and syringe programs (Coomber et al., 2015; Iversen et al., 2016; Kimergård & McVeigh, 2014a, 2014b) via specialist online forums (Chandler & McVeigh, 2013; Cohen et al., 2007; Parkinson & Evans, 2005) or through high schools (Buckley et al., 1988; Dunn & White, 2011; Johnstone, O'Malley, Bachman, Schulenberg, & Miech, 2015; Pallesen, Jøsendal, Johnsen, Larsen, & Molde, 2006; Tanner, Miller, & Alongi, 1995). Further, few of these studies have explored treatments received and none have examined the association between different types of medical interventions and service satisfaction from the AAS users' perspective. As AAS and PIEDs use among nonathletes increases, an important public health concern is to understand the experiences of adverse health effects and related health-seeking behaviors among general population AAS users. While the majority of surveys on AAS use collect only limited information about lifetime, past year, and past month use with no information on the experience of adverse effects and/or experience of health service engagement, the GDS 2015 survey tool measures a combination of patterns of AAS and PIEDs use and experience of adverse health issues and health-seeking behaviors.

Thus, the current study was able to investigate aspects of AAS use not well understood from previous research in a general population sample. Important limitations must also be considered.

Despite the very large sample size of the GDS, respondents are self-nominating and the sample is opportunistic. Further, the sample reporting recent steroid use is relatively small and virtually all report using recreational drugs in addition to AAS. Consequently, the sample used in the current study should not be considered representative of AAS using population. Relatively small numbers also preclude greater exploration of use by country of residence and therefore cannot account for variation in legislation and health service provision across different settings. Questions were limited to asking respondents about whether or not they had visited a family doctor but did not capture other forms of health service engagement such as visiting an emergency room or accessing injecting services, and therefore our findings cannot be applied to health-seeking behaviors more broadly.

Despite these limitations, the current study provides some important insights into health service engagement among a general population sample of AAS users. The results suggest that health service providers can better assist AAS users by testing for specific side effects of AAS use. As a common reason for not engaging with services was stigma, it is important that health service providers find subtle nuanced ways in which to demonstrate nonjudgmental attitudes toward AAS use. This may be achieved by encouraging broader conversations about mood, lifestyle, and well-being. Providing access to information about injecting, steroid dosing, and displaying information about steroid clinics in doctors' surgeries may also help to demonstrate to AAS users that doctors are nonjudgmental and willing to assist with monitoring health conditions associated with use.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Notes

1. The Wilcoxon–Mann–Whitney test is a nonparametric analog to the independent samples *t* test and does not require that the dependent variable is normally distributed.
2. Transgender individuals were dropped from the sample due to low numbers ($n = 6$).
3. We also tested for interaction effects between method of administration (0 = *oral*, 1 = *inject only*, and 2 = *oral and inject*) and all other adverse health effects, but none of the other interactions were significant.
4. Sex differences were assessed using Fischer's exact test. The association between age and indicators of satisfaction was assessed using ordinal logistic regression.

References

- Barratt, M., Ferris, J. A., & Winstock, A. R. (2014). Use of silk road, the online drug marketplace, in the United Kingdom, Australia and the United States. *Addiction, 109*, 774–783.
- Bojsen-Møller, J., & Christiansen, A. V. (2010). Use of performance-and image-enhancing substances among recreational athletes: A quantitative analysis of inquiries submitted to the Danish anti-doping authorities. *Scandinavian Journal of Medicine & Science in Sports, 20*, 861–867.
- Brennan, R., Wells, J., & Van Hout, M. (2016). The injecting use of image and performance-enhancing drugs (IPED) in the general population: A systematic review. *Health & Social Care in the Community*. doi:10.1111/hsc.12326
- Buckley, W. E., Yesalis, C. E. 3rd, Friedl, K. E., Anderson, W. A., Streit, A. L., & Wright, J. E. (1988). Estimated prevalence of anabolic steroid use among male high school seniors. *Journal of the American Medical Association, 260*, 3441–3445.

- Chandler, M., & McVeigh, J. (2013). *Steroids and image enhancing drugs 2013 survey results*. Liverpool, England: Centre for Public Health.
- Cohen, J., Collins, R., Darkes, J., & Gwartney, D. (2007). A league of their own: Demographics, motivations and patterns of use of 1955 male adult non-medical anabolic steroid users in the United States. *Journal of the International Society of Sports Nutrition*, 4, 12.
- Coomber, R., Pavlidis, A., Santos, G. H., Wilde, M., Schmidt, W., & Redshaw, C. (2015). The supply of steroids and other performance and image enhancing drugs (PIEDs) in one English city: Fakes, counterfeits, supplier trust, common beliefs and access. *Performance Enhancement & Health*, 3, 135–144.
- Davies, R., Smith, D., & Collier, K. (2011). Muscle dysmorphia among current and former steroid users. *Journal of Clinical Sports Psychology*, 5, 77–94.
- Dunn, M. (2010). The non-medical use of steroids in Australia: Results from a general population survey. *Australian and New Zealand Journal of Public Health*, 34, 531–532.
- Dunn, M., Henshaw, R., & McKay, F. (2016). Do performance and image enhancing drug users in regional Queensland experience difficulty accessing health services? *Drug and Alcohol Review*, 35, 377–382.
- Dunn, M., McKay, F. H., & Iversen, J. (2014). Steroid users and the unique challenge they pose to needle and syringe program workers. *Drug & Alcohol Review*, 33, 71–77.
- Dunn, M., & White, V. (2011). The epidemiology of anabolic–androgenic steroid use among Australian secondary school students. *Journal of Science and Medicine in Sport*, 14, 10–14.
- Global Drug Survey. (2015). Retrieved April 25, 2016, from <http://www.globaldrugsurvey.com>
- Griffiths, S., Henshaw, R., McKay, F., & Dunn, M. (2015). Post-cycle therapy for performance and image enhancing drug users: A qualitative investigation. *Performance Enhancement & Health*. Retrieved from <http://dx.doi.org/10.1016/j.peh.2016.11.002>
- Hanley Santos, G., & Coomber, R. (2016). The risk environment of anabolic-androgenic steroid users in the UK: Examining motivations, practices and accounts of use. *International Journal of Drug Policy*. Retrieved from <http://dx.doi.org/10.1016/j.drugpo.2016.11.005>
- Holland-Hall, C. (2007). Performance-enhancing substances: Is your adolescent patient using? *Pediatric Clinics of North America*, 54, 651–662.
- Hope, V. D., McVeigh, J., Marongiu, A., Evans-Brown, M., Smith, J., Kimergård, A., . . . Ncube, F. (2015). Injection site infections and injuries in men who inject image-and performance-enhancing drugs: Prevalence, risks factors, and healthcare seeking. *Epidemiology and Infection*, 143, 132–140.
- Ip, E. J., Barnett, M., Tenerowicz, M., & Perry, P. (2011). The anabolic 500 survey: Characteristics of male users versus nonusers of anabolic-androgenic steroids for strength training. *Pharmacotherapy*, 31, 757–766.
- Ip, E. J., Trinh, K., Tenerowicz, M., Pal, J., Lindfelt, T., & Perry, P. (2015). Characteristics and behaviors of older male anabolic steroid users. *Journal of Pharmacy Press*, 28, 450–456.
- Iversen, J., Hope, V. D., & McVeigh, J. (2016). Access to needle and syringe programs by people who inject image and performance enhancing drugs. *International Journal of Drug Policy*, 31, 199–200.
- Iversen, J., Topp, L., Wand, H., & Maher, L. (2013). Are people who inject performance and image-enhancing drugs an increasing population of Needle and Syringe Program attendees? *Drug and Alcohol Review*, 32, 205–207.
- Johnstone, L. D., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Miech, R. A. (2015). *Monitoring the future national survey results on drug use 1975-2014: Volume 2, College Students & Adults Ages 19-55*. Ann Arbor: Institute for Social Research, The University of Michigan.
- Kanayama, G., & Pope, H. G. (2012a). Illicit use of androgens and other hormones: Recent advances. *Current Opinion in Endocrinology, Diabetes and Obesity*, 19, 211–219.
- Kanayama, G., & Pope, H. G. (2012b). Misconceptions about anabolic-androgenic steroid abuse. *Psychiatric Annals*, 42, 371–375.
- Kimergård, A. (2015). A qualitative study of anabolic steroid use amongst gym users in the United Kingdom: Motives, beliefs and experiences. *Journal of Substance Use*, 20, 288–294.
- Kimergård, A., & McVeigh, J. (2014a). Environments, risk and health harms: A qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK. *BMJ Open*, 4, e005275.

- Kimergård, A., & McVeigh, J. (2014b). Variability and dilemmas in harm reduction for anabolic steroid users in the UK: A multi-area interview study. *Harm Reduction Journal, 11*, 19–31.
- Korika, P., Lenahan, P., & McVeigh, J. (1996). Non-medical use of androgens among women. *Journal of Occupational Psychology, Employment and Disability, 1*, 71–76.
- Lindqvist, A. S., Moberg, T., Eriksson, B. O., Ehrnborg, C., Rosén, T., & Fahlke, C. (2013). A retrospective 30-year follow-up study of former Swedish-elite male athletes in power sports with a past anabolic androgenic steroids use: A focus on mental health. *British Journal of Sports Medicine, 47*, 965–969.
- Maycock, B., & Howat, P. (2009). The barriers to illegal anabolic steroid use. *Drug: Education, Prevention and Policy, 12*, 317–325.
- McCabe, S., Brower, K., West, B., Nelson, T., & Wechsler, H. (2007). Trends in non-medical use of anabolic steroids by U.S. college students: Results from four national surveys. *Drug and Alcohol Dependence, 90*, 243–251.
- McVeigh, J., & Begley, E. (2016). Anabolic steroids in the UK: An increasing issue for public health. *Drugs: Education, Prevention and Policy*. Retrieved from <http://dx.doi.org/10.1080/09687637.2016.1245713>
- McVeigh, J., Beynon, C., & Bellis, M. (2003). New challenges for agency based syringe exchange schemes: Analysis of 11 years of data (1991-2001) in Merseyside and Cheshire, United Kingdom. *International Journal of Drug Policy, 14*, 399–405.
- Onakomaiya, M., & Henderson, L. P. (2016). Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors. *Psychopharmacology, 223*, 549–569.
- Pallesen, S., Jøsendal, O., Johnsen, B. H., Larsen, S., & Molde, H. (2006). Anabolic steroid use in high school students. *Substance Use & Use, 41*, 1705–1717.
- Parkinson, A. B., & Evans, N. A. (2005). Anabolic androgenic steroids: A survey of 500 users. *Medicine & Science in Sports & Exercise, 38*, 644–651.
- Pope, C. G., Pope, H. G., Menard, W., Fay, C., Olivardia, R., & Phillips, K. A. (2005). Clinical features of muscle dysmorphia among males with body dysmorphic disorder. *Body Image, 2*, 395–400.
- Pope, H. G., & Kanayama, G. (2015). Treatment of anabolic-androgenic steroid related disorders. In M. el-Guebaly, G. Carra, & N. Galanter (Eds.), *Textbook of addiction treatment: International perspectives* (pp. 621–636). Italy, Milan: Springer-Verlag.
- Pope, H. G., Kanayama, G., Athey, A., Ryan, E., Hudson, J. I., & Baggish, A. (2014). The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: Current best estimates. *American Journal of Addiction, 23*, 371–377.
- Pope, H. G., Kanayama, G., Ionescu-Pioggia, M., & Hudson, J. I. (2004). Anabolic steroid users' attitudes toward physicians. *Addiction, 99*, 1189–1194.
- Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2013). Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement. *Endocrine Reviews, 35*, 341–375.
- Quaglio, G., Fornasiero, A., Mezzelani, P., Lugoboni, F., & Lechi, A. (2009). Anabolic steroids: dependence and complications of chronic use. *Internal and Emergency Medicine, 4*, 289–296.
- Rasmussen, J., Selmer, C., Ostergren, P., Pedersen, K., Schou, M., Gustafsson, F., . . . Kistorp, C. (2016). Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: A case-control study. *PLOS One*. doi:10.1371/journal.pone.0161208
- Ravn, S., & Coffey, J. (2016). 'Steroids, it's so much an identity thing!' Perceptions of steroid use, risk and masculine body image. *Journal of Youth Studies, 19*, 87–102.
- Rowe, R., Berger, I., & Copeland, J. (2016). No pain, no gainz? Performance and image-enhancing drugs, health effects and information seeking. *Drugs: Education, Prevention and Policy*. Retrieved from <http://dx.doi.org/10.1080/09687637.2016.1207752>
- Sagoe, D., McVeigh, J., Bjørnebekk, A., Essilfie, M. S., Andreassen, C. S., & Pallesen, S. (2015). Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis. *Substance Abuse Treatment, Prevention and Policy, 10*, 1.

- Sagoe, D., Molde, H., Andreassen, C. S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. *Annals of Epidemiology*, *24*, 383–398.
- Seer, K., Fraser, S., Moore, D., & Murphy, D. (2015). Understanding and responding to anabolic steroid injecting and hepatitis C risk in Australia: A research agenda. *Drugs: Education, Prevention, Policy*, *22*, 449–455.
- Tanner, S., Miller, D., & Alongi, C. (1995). Anabolic steroid use by adolescents: Prevalence, motives and knowledge of risks. *Clinical Journal of Sports Medicine*, *5*, 108–115.
- Winstock, A., Lynskey, M., Borschmann, R., & Waldron, J. (2015). Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. *Journal of Psychopharmacology*, *29*, 698–703.
- Yu, J., Hildebrandt, T., & Lanzieri, N. (2015). Healthcare professionals' stigmatization of men with anabolic androgenic steroid use and eating disorders. *Body Image*, *15*, 49–53.

Author Biographies

Renee Zahnow is a research fellow at the University of Queensland in Brisbane, Australia. She has expertise in spatial and longitudinal analyses and has applied these expertise to examine spatiotemporal patterns of a range of social problems including crime, disorder, disaster effects, and fire. She has published in *Criminology*, *Journal of Urban Affairs*, *Journal of Transport Geography*, among others. Currently, she has an interest in applying spatial and longitudinal methods to better understand patterns of alcohol and other drug use in Australia and globally.

Jim McVeigh is the director of Public Health Institute at Liverpool John Moores University. He has worked within public health for nearly 30 years, holding various positions throughout his academic career. He has an international reputation within his academic specialism of human enhancement drug use and has co-authored more than 100 research reports, 50 peer-reviewed papers, and been invited to deliver keynote presentations and plenary papers at some of the most influential national and international conferences.

Jason Ferris is a senior research fellow in the Institute for Social Science Research at the University of Queensland (UQ), Brisbane, and holds an NHMRC Postdoctoral Fellowship. He leads the Drug Alcohol and Crime Research Program and works within the Research Methods and Social Statistics (ReMASS) Program. He is also an affiliate senior research fellow with the School of Social Science, UQ, and the chief biostatistician for the Global Drug Survey. His interests lie in application of sophisticated analytical modeling, including geographic information systems (GIS) and time-series analysis, using large-scale and population health data. He is involved in a number of key projects, including the evaluation and effectiveness of electronic surveillance tools for control drugs and drug diversion, reviewing the effectiveness of random breath testing mechanisms to reduce alcohol-related traffic crashes in Australia, measuring the extent of alcohol-fueled violence in Queensland, Australia, and measuring the upcoming legislative changes targeting alcohol-fueled violence. He has almost 15 years of social science and public health research experience with a well-established publication record with a strong focus on alcohol and other drug research. In September 2014, he received a highly commended Early Career Researcher Award within the Faculty of Humanities and Social Science and in September 2015, he received the Early Career Researcher Award.

Adam Winstock is a consultant addiction psychiatrist based in London where he is in charge of the care of people who use drugs in prison. He is also an honorary reader at the University College London, he was previously a consultant psychiatrist at the Maudsley Hospital, and a senior lecturer at the Institute of Psychiatry, Kings College London. He has published over 100 research papers and has developed particular clinical and research expertise in the areas of cannabis, new drugs, and chemsex. He is also the founder and director of the Global Drug Survey, the world's biggest annual survey of drug use trends, the architect of online and smartphone apps drugs meter and Drinks Meter, and the ultra brief feedback and assessment tool for cannabis use www.saferuselimits.co